Revilla-López Eva, Berastegui Cristina, Sáez-Giménez Berta, Lopez-Meseguer Manuel, Monforte Victor, Bravo Carlos, Sacanell Lacasa Judith, Romero Vielva Laura, Moreno Galdo Antonio, Roman Antonio
Servicio de Neumologia, Hospital Vall d'Hebron Barcelona, Universitat Autònoma de Barcelona, Barcelona, España.
Servicio de Neumologia, Hospital Vall d'Hebron Barcelona, Universitat Autònoma de Barcelona, Barcelona, España.
Arch Bronconeumol (Engl Ed). 2019 Mar;55(3):134-138. doi: 10.1016/j.arbres.2018.07.025. Epub 2018 Aug 18.
Long-term survival of lung transplantation (LT) patients is mainly limited by the development of chronic lung allograft dysfunction (CLAD). Lung retransplantation (LR) is an alternative for a selected population. The aim of this study was to review the LR experience in our center.
We conducted a retrospective study of patients undergoing LR between August 1990 and July 2017.
Fourteen LR out of a total of 998 (1.4%) LT were performed. Twelve patients (85.7%) underwent LR due to CLAD: 10 (71.4%) because of bronchiolitis obliterans syndrome and 2 (14.3%) due to restrictive allograft syndrome. LR was performed in 2 patients within 30 days of the first LT. In those who underwent LR due to CLAD, mean time between the first LT and LR was 48 months, and mean duration of invasive mechanical ventilation was 32 days. The increase in FEV after LR was 24±18%. The best spirometry values were observed after 7.3 months. Mean survival of the cohort was 43.8 months. In patients with bronchiolitis obliterans syndrome, mean survival was 63.4 months, while in those with restrictive allograft syndrome, it was 19.5 months. Only 1 of the 2 early LR patients survived.
LR is a therapeutic option in selected patients with CLAD, with acceptable survival. Indication for LR early after LT shows poor outcomes.
肺移植(LT)患者的长期生存主要受慢性肺移植功能障碍(CLAD)发展的限制。再次肺移植(LR)是部分特定患者群体的一种选择。本研究旨在回顾我们中心的LR经验。
我们对1990年8月至2017年7月期间接受LR的患者进行了一项回顾性研究。
在总共998例LT中,进行了14例LR(1.4%)。12例患者(85.7%)因CLAD接受LR:10例(71.4%)因闭塞性细支气管炎综合征,2例(14.3%)因限制性移植肺综合征。2例患者在首次LT后30天内接受了LR。在因CLAD接受LR的患者中,首次LT与LR之间的平均时间为48个月,有创机械通气的平均持续时间为32天。LR后第一秒用力呼气容积(FEV)增加了24±18%。最佳肺量计值在7.3个月后观察到。该队列的平均生存期为43.8个月。在闭塞性细支气管炎综合征患者中,平均生存期为63.4个月,而在限制性移植肺综合征患者中,为19.5个月。2例早期LR患者中仅1例存活。
LR是部分特定CLAD患者的一种治疗选择,生存期可接受。LT后早期进行LR的指征显示预后较差。